Neuroprotection for Parkinson’s disease: a new approach for a new millennium

Bibliography

• RIESS 0, KUHN W, KROGER R: Genetic influence on the development of Parkinson's disease. J. Neural (2000) 247\(Suppl. 2):II/ 69-11/74.
   Google Scholar
• QUIGLEY EM: Gastrointestinal dysfunction in Parkinson's disease. Semi]. Neural (1996) 16:245–250.
   PubMed Web of Science ®Google Scholar
• TAM J, NAKAJIMA K, HWANG EH et al.: Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur. J. Nucl. Med. (2000) 27:566–573.
   PubMedGoogle Scholar
• GASSER T: Genetics of Parkinson's disease. Ann. Neural (1998) 44(Suppl.):S53–S57.
   Google Scholar
• TANNER CM, OTTMAN R, GOLDMAN SM etal.: Parkinson's disease in twins: an etiologic study. JAMA (1999) 281:341–346.
   Google Scholar
• BROOKS DJ: The early diagnosis of Parkinson' disease. Ann. Neural (1998) 44(Suppl.):S10–S18.
   Google Scholar
• LANGSTON JW: Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann. Neural (1998) 44(Suppl.):S45–S52.
   Google Scholar
• OLANOW CW, TATTON WG: Etiology and pathogenesis of Parkinson's disease. Ann. Rev Neurosci. (1999) 22:123–144.
   PubMed Web of Science ®Google Scholar
• BETARBET R, SHERER TB, MACKENZIE G, GARCIA-OSUNA M, PANOV AV, GREENAMYRE JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature NeuroscL (2000) 3:1301–1306.
   PubMed Web of Science ®Google Scholar
• PERL DP, OLANOW CW, CALNE DB: Alzheimer's disease and Parkinson's disease; distinct entities or extremes of a spectrum of neurodegeneration? Ann. Neural (1998) 44(Suppl.):S19–S31.
   Google Scholar
• HIRSCH E, GRAYBIEL AM, AGID YA: Melanized dopaminergic neurones are differentially susceptible to degeneration in Parkinson's disease. Nature (1988) 334:345–348.
   PubMed Web of Science ®Google Scholar
• EHRINGER H, HORNYKIEWICZ 0: Verteilung von noradrenalin und dopamin (3-hydroxytyramiM im gehirn des menschen. Kiln. Woch. (1960) 38:1236–1239.
   PubMed Web of Science ®Google Scholar
• SANO I: Biochemistry of the extrapyramidal system. Frog. Neural ScL (1960) 5:42–48.
   Google Scholar
• BIRKMAYER W, HORNYKIEWICZ 0: Der L-dioxyphenylalanine. Wien. fah. Wocherischr. (1961) 73:787–788.
   PubMedGoogle Scholar
• COTZIAS GC, VAN WOERT MH, SCHIFFER LM: Aromatic amino acids and modification of parkinsonism. N Engl. J. Med. (1967) 276:374–379.
   PubMed Web of Science ®Google Scholar
• TOLOSA E, MARTI MJ, VALLEDEORIOLA F, MOLINUEVO JL: History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology (1998) 50\(Suppl. 6):52–S10.
   Google Scholar
• SHEFRIN SL: Therapeutic advances in idiopathic parkinsonism. Exp. Opin. Invest. Drugs (1999) 8:1565–1588.
   PubMedGoogle Scholar
• MARSDEN CD, PARKES JD: Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet (1977) 1:345–349.
   PubMed Web of Science ®Google Scholar
• DUNNETT SB, BORKLUND A: Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature (1999) 399(Suppl.):A32–A39.
   Google Scholar
• ••Comprehensive review that describes themolecular pathology of Parkinson's disease and the mechanisms of cell death in the substantia nigra with special focuss on neuroprotective anclior cell (gene) replacement therapies.
   Google Scholar
• DEIGNER H-P, HABERKORN U, KINSCHERF R: Apoptosis modulators in the therapy of neurodegenerative diseases. Exp. Opin. Investig. Drugs (2000) 9:747–764.
   PubMed Web of Science ®Google Scholar
• SCHACHTER SC, TARSY D: Remacemide: current status and clinical applications. Exp. Opin. Investig. Drugs (2000) 9:871–883.
   PubMed Web of Science ®Google Scholar
• FAHN S, COHEN G: The oxidant stresshypothesis in Parkinson's disease: evidence supporting it. Ann. Neural (1992) 32:804–812.
   PubMed Web of Science ®Google Scholar
• JENNER P, OLANOW CW: Understanding cell death in Parkinson's disease. Ann. Neural (1998) 44(Suppl.):572–584.
   Google Scholar
• FOLEY P, RIEDERER P: Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J. Neural (2000) 247\(Suppl. 2):11/82-II/94.
   Google Scholar
• GRONBLATT E, MANDEL S, YOUDIM MBH: MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J. Neural (2000) 247\(Suppl. 2)11/95-II/102.
   Google Scholar
• DRUKARCH B, VAN MUISWINKEL FL: Drug treatment of Parkinson's disease: time for phase II. Biochern. Phannacol (2000) 59:1023–1031.
   PubMed Web of Science ®Google Scholar
• SIAN J, GERLACH M, YOUDIM MBH, RIEDERER P: Parkinson's disease: a major hypokinetic basal ganglia disorder. J. Neural Trarisrn. (1999) 106:443–476.
   PubMed Web of Science ®Google Scholar
• RANDALL BL: Iron, aging, and human disease: historical background and new hypotheses. In: Iron and human disease. BL Randall (Ed.) CRC Press (1992):1–23.
   Google Scholar
• PARKINSON STUDY GROUP,DATATOP: A multicenter controlled clinical trial in early Parkinson" disease. Arch. Neural (1989) 46:1052–1060.
   PubMed Web of Science ®Google Scholar
• HAGAN JJ, MIDDLEMISS DN, SHARPE PC, POSTE GH: Parkinson's disease:prospects for improved drug therapy. Trends Pharmacol Sci. (1997) 18:156–163.
   PubMed Web of Science ®Google Scholar
• FINBERG JP, LAMENSDORF I, COMMISSIONG JW, YOUDIM MB: Pharmacology and neuroprotective properties of rasagiline. J. Neural Transm. (1996) 48(Suppl.):95–101.
   Google Scholar
• YOUDIM MB, GROSS A, FINBERG JP: Rasagiline [N-propargy1-1R(+)-aminoindanl, a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J. Phannacol. (2001) 132:500–506.
   Google Scholar
• HASTINGS TG: Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. I Neurochern. (1995) 64:919–924.
   PubMed Web of Science ®Google Scholar
• STOKES AH, HASTINGS TG, VRANA KE: Cytotoxic and genotoxic potential of dopamine. J. NeuroscL Res. (1999) 55:659–665.
   PubMed Web of Science ®Google Scholar
• XU Y, STOKES AH, FREEMAN WM, KUMER SC, VOGT BA, VRANA KE: Tyrosinase mRNA is expressed in human substantia nigra. Mal Brain Res. (1997) 45:159–162.
   PubMed Web of Science ®Google Scholar
• MATTAMMAL MB, STRONG R, LAKSHMI VM, CHUNG HD, STEPHENSON AH: Prostaglandin H synthase-mediated metabolism of dopamine: implication for Parkinson's disease. J. Neurochern. (1995) 64:1645–1654.
   PubMed Web of Science ®Google Scholar
• SPENCER PE, JENNER P, DANIEL SE,LEES AJ, MARSDEN CD, HALLIWELL B: Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochern. (1998) 71:2112–2122.
   PubMed Web of Science ®Google Scholar
• BIND OLI A, RIGOBELLO MP, DEEBLE DJ: Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol. Med. (1992) 13:391–405.
   PubMed Web of Science ®Google Scholar
• GRAHAM DG: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mal Pharmacol (1978) 14:633–643.
   PubMed Web of Science ®Google Scholar
• SMYTHIES J, GALZIGNA L: The oxidative metabolism of catecholamines in the brain: a review. Biochim. Biophys. Acta (1998) 1380:159–162.
   PubMed Web of Science ®Google Scholar
• ••This review deals with relationshipbetween dopamine-autooxidation and neuromelanin formation and summarizes the evidence that is available to demonstrate that the oxidative metabolism of catecholamines via their respective quinones occurs in vivo in the brain.
   Google Scholar
• D'ISCHIA M, PROTA G: Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update. Pigment Cell Res. (1997) 10:370–376.
   PubMedGoogle Scholar
• CARSTAM R, BRINCK C, HINDEMITH-AUGUSTSSON A, RORSMAN H, ROSENGREN E: The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta (1991) 1097:152–160.
   PubMed Web of Science ®Google Scholar
• PALUMBO A, D'ISCHIA M, MISURACA G, DE MARTINO L, PROTA G: Iron- and peroxide-dependent conjugation of dopamine with cysteine: oxidative routes to the novel brain metabolite 5-S-cysteinyldopamine. Biochim. Biophys. Acta (1995) 1245:255–261.
   PubMed Web of Science ®Google Scholar
• SULZER D, BOGULAVSKY J, LARSENKE et al.: Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. USA (2000) 97:11869–11874.
   PubMed Web of Science ®Google Scholar
• WEINGARTEN P, ZHOU Q-Y: Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors. j Neurochem. (2001) 77:776–785.
   PubMed Web of Science ®Google Scholar
• NIRENBERG MJ, CHAN J, LIU Y, ED WARDS RH, PICKEL VM: Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurones: potential sites for somatodendritic storage and release of dopamine. J. Neurosci. (1996) 16:4135–4145.
   PubMed Web of Science ®Google Scholar
• MUTHANE U, YASHA TC, SHANKAR SC: Low numbers and no loss of melanized nigral neurones with increasing age in normal human brain in India. Ann. Neural. (1998) 43:283–287.
   PubMed Web of Science ®Google Scholar
• WANG W, BALLATORI N: Endogenous glutathione conjugates: occurrence and biological functions. Pharmacol Rev (1998) 50:335–355.
   PubMed Web of Science ®Google Scholar
• SEGURA-AGUILAR J: Peroxidase activityof liver microsomal vitamin D 25-hydroxylase and cytochrome P450 1A2 catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome. Biochem. Mal Med. (1996) 58:122–129.
   PubMedGoogle Scholar
• SEGURA-AGUILAR J, METODIEWA D,WELCH CJ: Metabolic activation of dopamine o-quinones to o-semiquinone by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta (1998) 1381:1–6.
   PubMed Web of Science ®Google Scholar
• BAEZ S, LINDERSON Y, SEGURA-AGUILAR J: Superoxide dismutase and catalase enhance autooxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem. Mal Med. (1995) 54:12–18.
   PubMedGoogle Scholar
• MEISTER A, ANDERSON ME: Glutathione. Ann. Rev Biochem. (1983) 52:711–760.
   PubMed Web of Science ®Google Scholar
• LOTHARIUS J, O'MALLEY KL: The parkinsonism-inducing drug 1-methy1-4-phenylpyridinium triggers intracellular dopamine oxidation. j Biol. Chem. (2000) 275:38581–38588.
   PubMed Web of Science ®Google Scholar
• RAVINDRANATH V, ANANDAHEERTHAVARADA HK, SHANKAR SK: NADPH cytochrome P-450 reductase in rat, mouse and human brain. Biochem. Pharmacol (1990) 39:1013–1018.
   PubMed Web of Science ®Google Scholar
• RESCIGNO A, RINALDI AC, SANJUST E: Some aspects of tyrosine secondary metabolism. Biochem. Pharmacol (1998) 56:1089–1096.
   PubMed Web of Science ®Google Scholar
• BERNHARDT R: Cytochrome P450: structure, function, and generation of reactive oxygen species. Rev. Physic] Biochem. Pharmacol (1996) 127:137–221.
   PubMed Web of Science ®Google Scholar
• MEYER UA: Overview of enzymes of drug metabolism. I Pharmacokin Biopharm. (1996) 24:449–459.
   PubMedGoogle Scholar
• WILKINSON J IV, CLAPPER ML: Detoxification enzymes and chemoprevention. Proc. Soc. Esp. Biol. Med. (1997) 216:192–200.
   PubMed Web of Science ®Google Scholar
• LIND C, HOCHSTEIN P, ERNSTER L: DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch. Biochem. Biophys. (1982) 216:178–185.
   PubMed Web of Science ®Google Scholar
• SEGURA-AGUILAR J, LIND C: On the mechanism of the Mn3+-induced neurotoxicity of dopamine: prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chem. Biol. Interact. (1989) 72:309–324.
   PubMed Web of Science ®Google Scholar
• CADENAS E: Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem. Pharmacol (1995) 49:127–140.
   PubMed Web of Science ®Google Scholar
• CADENAS E, HOCHSTEIN P, ERNSTER L: Pro- and antioxidant functions of quinones and quinone reductases in mammalian cells. Adv. Enzymol. (1992) 65:97–146.
   PubMedGoogle Scholar
• ZHANG P, DAMIER P, HIRSCH EC et al.: Preferential expression of superoxide dismutase messenger RNA in melanized neurones in human mesencephalon. Neuroscience (1993) 55:167–175.
   PubMed Web of Science ®Google Scholar
• BAEZ S, SEGURA-AGUILAR J, WIDERSTEN M, JOHANSSON A-S, MANNERVIK B: Glutathione transferases catalyze the detoxification of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. (1997) 324:25–28.
   PubMed Web of Science ®Google Scholar
• SEGURA-AGUILAR J, BAEZ S, WIDERSTEN M, WELCH CJ, MANNERVIK B: Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxification of the dopamine metabolite aminochrome. Biol. Chem. (1997) 272:5727–5731.
   Web of Science ®Google Scholar
• MURPHY TH, SO AP, VINCENT SR: Histochemical detection of quinone reductase activity in situ using LY 83583 reduction and oxidation. j Neurochem. (1998) 70: 2156–2164.
   PubMed Web of Science ®Google Scholar
• SCHULTZBERG M, SEGURA-AGUILAR J, LIND C: Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience (1988) 27:763–776.
   PubMed Web of Science ®Google Scholar
• PRESTERA T, HOLTZCLAW WD, ZHANG Y, TALALAY P: Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc. Natl. Acad. Sci. USA (1993) 90:2965–2969.
   PubMed Web of Science ®Google Scholar
• PRIMIANO T, SUTTER T, KENSLER
   Google Scholar
• TW: Antioxidant-inducible genes. Adv. Pharmacol. (1997) 38:293-328. This paper not only provides a comprehensive list of detoxication and antioxidant genes and their typical inducers but also gives a overview of the various transcriptional mechanisms involved.
   Google Scholar
• PROCHASKA HJ, DE LONG MJ, TALALAY P: On the mechanisms of induction of cancer-protective enzymes: a unifying proposal. Proc. Natl. Acad. Sci. USA (1985) 82:8232–8236.
   PubMed Web of Science ®Google Scholar
• HAYES JD, ELLIS EM, NEAL GE, HARRISON DJ, MANSON MM: Cellular response to cancer chemopreventive agents: contribution of the antioxidant responsive element to the adaptive response to oxidative and chemical stress. Biochem. Soc. Symp. (1999) 64:141–168.
   PubMedGoogle Scholar
• ••This excellent review, that describes themodulation of drug metabolism and the induction of antioxidant capacity by chemopreventive agents, provides detailed insight into the pivotal role of the anti-oxidant responsive element (ARE) in the induction of detoxification enzymes.
   Google Scholar
• OTIENO MA, KENSLER TW, GUYTON KZ: Chemoprotective 3H-1,2-dithiole-3-thione induces antioxidant genes in vivo. Free Radic. Biol. Med. (2000) 28:944–952.
   PubMed Web of Science ®Google Scholar
• PAYEN L, COURTOIS A, LOEWERT M, GUILLLOUZO A, FARDEL 0: Reactive oxygen species-related induction of multidrug resistance-associated protein 2 expression in primary hepatocytes exposed to sulforaphane. Biochem. Biophys. Res. Commun. (2001) 282:257–263.
   PubMed Web of Science ®Google Scholar
• PROCHASKA HJ, TALALAY P: Regulatory mechanisms of monofunctional and bifunctional anticarcinogenic enzyme inducers in murine liver. Cancer Res. (1988) 48:4776–4782.
   PubMed Web of Science ®Google Scholar
• ROWLANDS JC, GUSTAFSSON J-A: Aryl hydrocarbon receptor-mediated signal transduction. Grit. Rev Toxicol. (1997) 27:109–134.
   PubMed Web of Science ®Google Scholar
• OKEY AB, RIDDICK DS, HARPER PA:Molecular biology of the aromatic hydrocarbon (dioxin) receptor. Trends Pharmacol. Sci. (1994) 15:226–232.
   PubMed Web of Science ®Google Scholar
• DINKOVA-KOSTOVA AT, MASSIAH MA, BOZAK RE, HICKS RJ, TALALAY P: Potency of michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Sci. USA (2001) 98:3404–3409.
   PubMed Web of Science ®Google Scholar
• SPENCER SR, XUE L, KLENZ EM, TALALAY P: The potency of inducers of NAD (P)H: (quinone-acceptor) oxidoreductase parallels their efficiency as substrates for glutathione transferases: structural and electronic correlations. Biochem. J (1991) 273:711–717.
   PubMed Web of Science ®Google Scholar
• TALALAY P, DE LONG MJ, PROCHASKA HJ: Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl. Acad. Sci. USA (1988) 85:8261–8265.
   PubMed Web of Science ®Google Scholar
• PRIMIANO T, SUTTER TR, KENSLER TW: Redox regulation of genes that protect against carcinogens. Comp. Biochem. Physiol. (1997) 118B:487–497.
   Google Scholar
• JAISWAL AK: Antioxidant response element. Biochem. Pharmacol. (1994) 48:439–444.
   PubMed Web of Science ®Google Scholar
• DHAKSHINAMOORTHY S, LONG DJ II, JAISWAL AK: Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr. Topics Cell. Regul. (2000) 36:201–216.
   PubMedGoogle Scholar
• ITOH K, WAKABAYASHI N, KATOH Y et al.: Keapl represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev (1999) 13:76–86.
   PubMed Web of Science ®Google Scholar
• HUANG H-C, NGUYEN T, PICKETT CB: Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc. Natl. Acad. Sci. USA (2000) 97:12475–12480.
   PubMed Web of Science ®Google Scholar
• YU R, CHEN C, MO Y-Y et al.: Activationof mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. j Biol. Chem. (2000) 275:39907–39913.
   PubMed Web of Science ®Google Scholar
• KONG A-NT, YU R, CHEN C, MANDLEKAR S, PRIMIANO T: Signal transduction events elicited by natural products: role of MAPK and caspase pathways in homeostatic response and induction of apoptosis. Arch. Pharm. Res. (2000) 23:1–16.
   PubMed Web of Science ®Google Scholar
• WOLF CR: Chemoprevention: increased potential to bear fruit. Proc. Nati Acad. Sci. USA (2001) 98:2941–2943.
   PubMed Web of Science ®Google Scholar
• HAYES JD, CHANAS SA, HENDERSON CJ et al.: The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem. Soc. Trans. (2000) 28:33–41.
   PubMed Web of Science ®Google Scholar
• MCMAHON M, ITOH K, YAMAMOTO M et al.: The cap'n'collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. (2001) 61:3299–3307.
   PubMed Web of Science ®Google Scholar
• CHAN JY, HAN X-D, KAN YW: An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Nati Acad. Sci. USA (2001) 98:4611–4616.
   PubMed Web of Science ®Google Scholar
• RAMOS-GOMEZ M, KWAK M-K, DOLAN PM et al.: Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Nati Acad. Sci. USA (2001) 98:3410–3415.
   PubMed Web of Science ®Google Scholar
• AHLGREN-BECKENDORF JA, REISING AM, SCHANDER MA, HERDLER JW, JOHNSON JA: Coordinate regulation of NAD (P)H:quinone oxidoreductase and glutathione-S-transferases in primary cultures of rat neurones and glia: role of the antioxidantielectrophile responsive element. Clia (1999) 25:131–142.
   Google Scholar
• MURPHY TH, YU J, NG R et at.: Preferential expression of antioxidant response element mediated gene expression in astrocytes. j Neurochem. (2001) 76:1670–1678.
   Google Scholar
• DRUKARCH B, SCHEPENS E, JONGENELEN CAM, STOOF JC, LANGEVELD CH: Astrocyte-mediated enhancement of neuronal survival is abolished by glutathione deficiency. Brain Res. (1997) 770:123–130.
   PubMed Web of Science ®Google Scholar
• DRUKARCH B, SCHEPENS E, STOOF JC, LANGEVELD CH, VAN MUISWINKEL FL: Astrocyte-enhanced neuronal survival is mediated by scavenging of extracellular reactive oxygen species. Free Radic. Biol. Med. (1998) 25:217–220.
   PubMed Web of Science ®Google Scholar
• FLIER J, VAN MUISWINKEL FL, JONGENELEN CAM, RIEMERS FM, DRUKARCH B: Alpha-lipoic acid, alike anethole dithiolethione, but in contrast to N-acetylcysteine stimulates endogenous antioxidant pathways in cultured astroglial cells. (Submitted.)
   Google Scholar
• DRINGEN R, HAMPRECHT B, DRUKARCH B: Anethole dithiolethione, a putative neuroprotectant, increases intracellular and extracellular glutathione levels during starvation of cultured astroglial cells. Naurgai Schmiedebergs Arch. Pharmacy]. (1998) 358:616–622.
   PubMed Web of Science ®Google Scholar
• DRUKARCH B, SCHEPENS E, STOOF JC, LANGEVELD CH: Anethole dithiolethione prevents oxidative damage in glutathione-depleted astrocytes. Eur. Pharmacy]. (1997) 329:259–262.
   PubMed Web of Science ®Google Scholar
• CHRISTEN M-0: Anethole dithiolethione: biochemical considerations. Methods Erizymol. (1995) 252:316–323.
   PubMed Web of Science ®Google Scholar
• BEN-YOSEPH 0, BOXER PA, ROSS BD: Assessment of the role of the glutathione and pentose phosphate pathway in the protection of primary cerebrocortical cultures from oxidative stress. j Neurochern. (1996) 66:2329–2337.
   PubMed Web of Science ®Google Scholar
• DUFFY S, SO A, MURPHY TH: Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. _J. Neurochem. (1998) 71:69–77.
   PubMed Web of Science ®Google Scholar
• RAVINDRANATH V: Metabolism of xenobiotics in the central nervous system: Implications and challenges. Biochem. Pharmacy]. (1998) 56:547–551
   PubMed Web of Science ®Google Scholar
• MANDEL S, GRONBLATT E, LEVITES Y, MAOR G, YOUDIM MBH: Molecular events in neurodegeneration and neuroprotection in Parkinson's disease and its MPTP model as assessed by cDNA microarray. Parkinsonism & Related Disord. (2001) 7(Suppl.):55–56.
   Google Scholar
• HEISS E, HERHAUS C, KLIMO K, BARTSCH H, GERHAUSER C: Nuclear factor-KB is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. j Biol. Chem. (2001) 276:32008–32015.
   PubMed Web of Science ®Google Scholar
• SEN CK, TRABER K, PACKER L: Inhibition of NF-icB activation in human T-cell lines by anetholdithiolthione. Biochem. Biophys. Res. Commun. (1996) 218:148–153.
   PubMed Web of Science ®Google Scholar
• YAO K-S, O'DWYER PJ: Involvement of NF-icB in the induction of NAD (P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C. Biochem. Pharmacy]. (1995) 49:275-282. Affiliation Benjamin Drukarclir & Freek L van Muiswinkel 'rAuthor for correspondence Department of Medical Pharmacology, Research Institute Neurosciences, Vrije Universiteit Medical Center, vd Boechorststraat 7, 1081 BT Amsterdam, The Netherlands Tel.: +31 204448107; Fax: +31 204448100; E-mail: [email protected]
   Google Scholar